Nordic Science Investments
VC Fund
Helsinki, Finland
Nordic Science Investments is a VC fund dedicated to transforming groundbreaking scientific research into globally successful companies. NSI aims to bridge the gap between academia and business by investing in science-based startups and university spinouts that address global challenges. With a focus on especially deeptech, healthtech, and life sciences, Nordic Science Investments supports visionary founders from the New Nordics in building transformative companies. The fund drives progress from pre-seed through to selected Series A stages, empowering innovation and growth.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 83%
- Fund size:
- $34M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Nordic Science Investments invests in
Stages Nordic Science Investments invests in
Countries Nordic Science Investments invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $373k–$4.6M
- Pre-Seed
- $380k–$837k
- Series A
- $2.9M–$34M
Investment Focus
Industry
- Biotechnology 5 (28%)
- Medical 4 (22%)
- Health Diagnostics 3 (17%)
- Health Care 2 (11%)
- Apps 1 (6%)
Stage
- Seed 7 (39%)
- Pre-Seed 6 (33%)
- Series A 3 (17%)
- Convertible Note 1 (6%)
Country
- Finland 8 (44%)
- Sweden 3 (17%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexandra Gylfe
Founding Partner
|
Founding Partner | Total investments: 5 | Find email | |
Matti Hautsalo
Founding Partner
|
Founding Partner | Total investments: 3 | Find email | |
Mart Maasik
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered | $34.2M / Series A / Sep 24, 2026 | ||
| Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D spatial analysis to speed up drug discovery. | $4.6M / Seed / Feb 17, 2026 | ||
| Perfat Technologies is a health-based technology company that develops fat-management applications based on healthy vegetable oils. | $2.9M / Series A / Sep 10, 2025 | ||
| Bringing hearing care into primary care through seamless, data-driven diagnostics solutions. | Pre-Seed / Jun 09, 2025 | ||
| AIATELLA transforms cardiovascular diagnostics by harnessing AI to automate quantification, detection, and interpretation of medical images across multiple imaging modalities. Their technology boosts efficiency, ensures standardized analysis, and enables precision medicine, addressing the global challenges of radiologist shortages and the risingburden of cardiovascular diseases. | $2.3M / Seed / Jun 04, 2025 | ||
| Mu-ray.tech is focused on advancing the field of medical diagnostics and industrial quality control. mu-ray.tech is developing a groundbreaking technology for the rapid, safe and accurate 3D-imaging of the chemical composition of scanned objects, serving critical needs in industrial quality control and medical diagnostics. The technology is basedon Muon Beam Imaging (MBI), an innovative technology leveraging Laser Plasma Accelerator-based artificial muon sources, new generation particle detector systems and AI. In industry, we are working with the partners in the heavy, aerospace, and defence domains.mu-ray.tech operates at the three sites: DESY in Hamburg (hardware), Tehnopol in Tallinn (algorithms and software), and Bradfield Centre in Cambridge (algorithms, business development). Our main collaboration on the MBI technology partners are GScan in Estonia and UK, DESY in Hamburg, the University of Cambridge, and KBFI in Tallinn. | $170.3K / Convertible Note / Jun 01, 2025 | ||
| RNatives specializes in the field of biotechnology, focusing on the development of innovative RNA-based therapies. The company's expertise lies in RNA activation, particularly targeting VEGFA for the treatment of cardiovascular diseases. RNatives is dedicated to advancing its lead programs through rigorous research and development, aiming tooffer novel therapeutic options for conditions with unmet medical needs. With a team of skilled professionals, RNatives is committed to pushing the boundaries of biotechnology to improve patient outcomes. | $1.6M / Seed / May 27, 2025 | ||
| Next generation Dried Blood Spot sampling – separating cells and plasma at the point of collection. | $1.8M / Seed / May 09, 2025 | ||
| Solid IO believes cancer care should be as precise and personal as possible. Solid IO’s tumor-on-chip platform is transforming oncology, delivering real-time, patient-specific insights that empower clinicians to make life-changing treatment decisions. With Solid IO, the next era of precision oncology | $836.9K / Pre-Seed / Feb 24, 2025 | ||
| Phenaros Pharmaceuticals is a Swedish spin-off drug discovery company from Uppsala University. We employ phenomics (large-scale cell morphological profiling) in conjunction with automation and AI to discover and repurpose medications for uncommon diseases. Aside from developing an in-house drug discovery pipeline, we also form collaborations toprovide access to our discovery platform. | Pre-Seed / Jan 30, 2025 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nordic Science Investments invest in?
Nordic Science Investments invests primarily in Biotechnology, Medical and Health Diagnostics startups, most often at Seed and Pre-Seed stage. Most of the 18 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Nordic Science Investments invest in?
Nordic Science Investments typically joins rounds of $373k–$4.6M at Seed, $380k–$837k at Pre-Seed and $2.9M–$34M at Series A. These are whole funding-round sizes, not Nordic Science Investments's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Nordic Science Investments took part in.
How do I contact Nordic Science Investments?
Public channels for Nordic Science Investments include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nordic Science Investments?
The team at Nordic Science Investments includes Alexandra Gylfe (Founding Partner), Matti Hautsalo (Founding Partner) and Mart Maasik (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
